GET DAILY SIGNALSCVS Health (CVS) Delivers Strong Q3 Results but Shares Decline on Split Plans
Key Takeaways
- CVS Health reported third-quarter 2026 total revenues of $108.4 billion, up 5.4% year over year and above the consensus estimate of roughly $104.7 billion.
- Adjusted earnings per share (EPS, or profit per share excluding one-time items) came in at $2.09, topping the consensus estimate of $1.65, while GAAP diluted EPS (the standard accounting measure) was $1.68.
- The company raised its full-year 2026 guidance across the board, including adjusted EPS to at least $8.20 and operating cash flow to at least $15.5 billion.
- The Health Care Benefits segment, led by Aetna, showed the biggest improvement, with adjusted operating income rising to $912 million from $314 million a year earlier.
- Despite the earnings beat, shares fell sharply after the company confirmed plans to split into two independent public companies by the first half of 2028.
Why This Quarter Carries Extra Weight
CVS Health operates at the crossroads of retail pharmacy, pharmacy benefit management, and health insurance through its Aetna unit. Last year’s third quarter included a large goodwill impairment that skewed the comparison, so this report gave a clearer look at ongoing margin recovery efforts. Investors were also monitoring whether elevated medical costs, a challenge across managed care, might be easing. On top of the numbers, management confirmed a strategic separation of its health care and retail pharmacy operations into two standalone companies.
The Quarter in Detail
For the three months ended September 30, 2026, CVS reported total revenues of $108.4 billion, a 5.4% increase from $102.9 billion a year earlier and above the consensus estimate of about $104.7 billion. Adjusted EPS rose to $2.09 from $1.60 in the prior-year period, comfortably exceeding the $1.65 consensus. GAAP diluted EPS was $1.68, a sharp swing from the prior-year loss of $3.13 per share.
Segment results showed improvement in most areas. The Health Care Benefits division posted revenue of $36.9 billion (up 2.4%) and adjusted operating income of $912 million, up from $314 million, while its medical benefit ratio improved to 91.3% from 92.8%. Health Services generated $54.0 billion in revenue (up 9.5%) and adjusted operating income of $2.1 billion. Pharmacy & Consumer Wellness revenue declined 2% to $35.5 billion, though adjusted operating income still grew more than 10%.
Management raised its full-year 2026 adjusted EPS outlook to at least $8.20 (from $7.90–$8.10), its revenue outlook to at least $420 billion, and its operating cash flow outlook to at least $15.5 billion (up from $11.5 billion). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and the Breakup News
Despite beating expectations on both revenue and adjusted earnings and raising full-year guidance, CVS shares declined on the day of the report. The reaction stemmed mainly from confirmation of the corporate separation: the health care solutions business (including Aetna, CVS Caremark, and Oak Street Health) will split from the retail pharmacy operations, branded CVS Pharmacy, with completion targeted for the first half of 2028. Execution risk and near-term disruption appear to have outweighed the solid quarterly results, with the stock trading lower in double-digit percentage terms intraday.
Key Themes to Follow
Looking ahead, several areas tied to this report will matter most. The announced separation creates a multi-year execution story, and updates on timing, capital structure, and leadership will draw attention. The margin recovery at Aetna remains central; the medical benefit ratio improvement to 91.3% is positive, but management stayed cautious on medical cost trends. Sustained progress supports the upgraded adjusted EPS target of at least $8.20.
The Health Services segment faces a tougher setup into 2027, with management expecting adjusted operating income of at least $7 billion next year and describing it as a trough period before growth resumes. Finally, the company pointed to 2027 adjusted EPS of at least $8.65, implying roughly 13% growth from the 2026 baseline. How well these targets are met while managing the restructuring will shape the next phase of the story. From what I see, the AI Trend Prediction Engine offers useful context on similar past separations.
AI Tools in My Research Process
When evaluating earnings like these, I often rely on Tickeron’s AI Screener to quickly scan for comparable companies and technical setups. The tool lets me apply filters for industry, fundamentals, and AI-driven signals in one place, helping confirm whether the patterns I’m seeing in CVS are unique or sector-wide. It streamlines the process without replacing my own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVS in +2.59% Uptrend, advancing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CVS moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 160 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 24 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 48 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.467) is slightly lower than the industry average of (3.359). P/E Ratio (23.929) is within average values for comparable stocks, (126.681). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement